{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T20:02:12Z","timestamp":1787688132215,"version":"build-2784847793"},"reference-count":41,"publisher":"Impact Journals, LLC","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,5,16]]},"DOI":"10.18632\/oncotarget.12953","type":"journal-article","created":{"date-parts":[[2016,10,28]],"date-time":"2016-10-28T01:37:12Z","timestamp":1477618632000},"page":"33844-33854","source":"Crossref","is-referenced-by-count":20,"title":["Prognostic impact of<i>fibroblast growth factor receptor 2<\/i>gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers"],"prefix":"10.18632","volume":"8","author":[{"given":"Seyoung","family":"Seo","sequence":"first","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Joon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Ryun","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baek-Yeol","family":"Ryoo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Soo","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Soon","family":"Na","sequence":"additional","affiliation":[{"name":"Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Kyung","family":"Lee","sequence":"additional","affiliation":[{"name":"Asan Institute for Life Science, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon-Koo","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/annonc\/mdh422","article-title":"Palliative chemotherapy for advanced gastric cancer","volume":"15","author":"Hejna","year":"2004","journal-title":"Ann Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4143\/crt.2016.092","article-title":"Prediction of Cancer Incidence and Mortality in Korea, 2016","volume":"48","author":"Lee","year":"2016","journal-title":"Cancer Res Treat"},{"key":"4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2009.01.004","article-title":"Gastric cancer","volume":"71","author":"Van Cutsem","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"5","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Ajani","year":"2006","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Norman","year":"2008","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/annonc\/mdn717","article-title":"Capecitabine\/cisplatin versus 5-fluorouracil\/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial","volume":"20","author":"Santamaria","year":"2009","journal-title":"Ann Oncol"},{"key":"8","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.2009.25.4706","article-title":"Multicenter phase III comparison of cisplatin\/S-1 with cisplatin\/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial","volume":"28","author":"Falcon","year":"2010","journal-title":"J Clin Oncol"},{"key":"9","first-page":"67","article-title":"Recent advances in chemotherapy for advanced gastric cancer","volume":"2","author":"Ryu","year":"2010","journal-title":"Asia Pac J Oncol Hematol"},{"key":"10","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Hill","year":"2010","journal-title":"Lancet"},{"key":"11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Komatsu","year":"2014","journal-title":"Lancet Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","article-title":"Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study","volume":"29","author":"Kang","year":"2011","journal-title":"J Clin Oncol"},{"key":"13","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","article-title":"Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study","volume":"31","author":"Ferry","year":"2013","journal-title":"J Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","article-title":"Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial","volume":"14","author":"Celik","year":"2013","journal-title":"Lancet Oncol"},{"key":"15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Schlessinger","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cytogfr.2005.01.007","article-title":"Mechanisms underlying differential responses to FGF signaling","volume":"16","author":"Basilico","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"17","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1038\/onc.2009.489","article-title":"Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets","volume":"29","author":"Reis-Filho","year":"2010","journal-title":"Oncogene"},{"key":"18","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1155\/2001\/981218","article-title":"CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors","volume":"22","author":"Kallioniemi","year":"2001","journal-title":"Anal Cell Pathol"},{"key":"19","first-page":"3541","article-title":"Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers","volume":"61","author":"Park","year":"2001","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0165-4608(93)90217-A","article-title":"DNA amplification in human gastric carcinomas","volume":"65","author":"Shiloh","year":"1993","journal-title":"Cancer Genet Cytogenet"},{"key":"21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2011.603","article-title":"FGFR2 gene amplification and clinicopathological features in gastric cancer","volume":"106","author":"Yamada","year":"2012","journal-title":"Br J Cancer"},{"key":"22","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bjc.2013.802","article-title":"FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study","volume":"110","author":"Kilgour","year":"2014","journal-title":"Br J Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.humpath.2011.12.002","article-title":"Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma","volume":"43","author":"Kim","year":"2012","journal-title":"Hum Pathol"},{"key":"24","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1158\/1078-0432.CCR-13-0190","article-title":"Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer","volume":"19","author":"Kay","year":"2013","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Bordas","year":"2012","journal-title":"Cancer Discov"},{"key":"26","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","article-title":"FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547","volume":"19","author":"Zhang","year":"2013","journal-title":"Clin Cancer Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1053\/j.gastro.2006.08.030","article-title":"A novel molecular targeting compound as K-samII\/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer","volume":"131","author":"Hirakawa","year":"2006","journal-title":"Gastroenterology"},{"key":"28","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1158\/0008-5472.CAN-10-1489","article-title":"GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling","volume":"70","author":"Gyuris","year":"2010","journal-title":"Cancer Res"},{"key":"29","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1309\/AJCPNFLSMWWPP8DR","article-title":"FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry","volume":"143","author":"Kang","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00280-011-1561-8","article-title":"A prognostic model in patients who receive chemotherapy for metastatic or recurrent gastric cancer: validation and comparison with previous models","volume":"68","author":"Kang","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"31","first-page":"5055","article-title":"Amplification of FGFR2 Gene in Patients with Advanced Gastric Cancer Receiving Chemotherapy: Prevalence and Prognostic Significance","volume":"35","author":"Shimada","year":"2015","journal-title":"Anticancer Res"},{"key":"32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.18632\/genesandcancer.96","article-title":"Prognostic impact of KRAS mutant type and MET amplification in metastatic and recurrent gastric cancer patients treated with first-line S-1 plus cisplatin chemotherapy","volume":"7","author":"Yamaguchi","year":"2016","journal-title":"Genes Cancer"},{"key":"33","first-page":"1373","article-title":"Immunohistochemical detection of K-sam protein in stomach cancer","volume":"2","author":"Terada","year":"1996","journal-title":"Clin Cancer Res"},{"key":"34","first-page":"875","article-title":"Co-expression of keratinocyte growth factor and K-sam is an independent prognostic factor in gastric carcinoma","volume":"21","author":"Hirakawa","year":"2009","journal-title":"Oncol Rep"},{"key":"35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","article-title":"A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets","volume":"61","author":"Lim","year":"2012","journal-title":"Gut"},{"key":"36","first-page":"301","article-title":"Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy","volume":"61","author":"Kang","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.canlet.2014.07.021","article-title":"Mutually exclusive FGFR2, HER2, and KRAS gene amplifications in gastric cancer revealed by multicolour FISH","volume":"353","author":"Tan","year":"2014","journal-title":"Cancer Lett"},{"key":"38","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1038\/bjc.2014.61","article-title":"HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma","volume":"110","author":"Qian","year":"2014","journal-title":"Br J Cancer"},{"key":"39","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/jco.2015.33.15_suppl.4014","article-title":"A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor Receptor 2 (FGFR2) polysomy or gene amplification (amp): SHINE study","volume":"33","author":"Kilgour","year":"2015","journal-title":"J Clin Oncol"},{"key":"40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.canlet.2011.03.015","article-title":"A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells","volume":"307","author":"Hirakawa","year":"2011","journal-title":"Cancer Lett"},{"key":"41","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00432-016-2143-2","article-title":"Value of FGFR2 expression for advanced gastric cancer patients receiving pazopanib plus CapeOX (capecitabine and oxaliplatin)","volume":"142","author":"Park","year":"2016","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12953","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:39:50Z","timestamp":1601167190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.12953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":41,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2017,5,16]]}},"alternative-id":["12953","27802183"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.12953","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,27]]}}}